Panea et al. (2019)

Summary of novel genes

Entity Total Tier 1 Tier 2 Tier 2 Pass Tier 2 Fail Fail Rate
BL 40 4 35 13 22 55%
--- config: sankey: showValues: true linkColor: target width: 600 height: 300 nodeAlignment: right prefix: '(' suffix: ' genes)' --- sankey-beta New to this study, BL Tier 1, 4 New to this study, BL Tier 2, 36 BL Tier 2, Pass QC, 13 BL Tier 2, Fail QC, 23

Novel genes reported in this study

Tier 1

Novel gene BL tier
BMP7 1
EIF4A1 1
EPPK1 1
HNRNPU 1

Tier 2

Novel Gene BL tier Average variant quality QC outcome
HIST1H3I 2 ★ ★ ★ ★ ☆ Pass
CXCR4 2 ★ ★ ★ ★ ☆ Pass
IRF8 2 ★ ★ ★ ★ ☆ Pass
MCL1 2 ★ ★ ★ ★ ☆ Pass
CD83 2 ★ ★ ★ ☆ ☆ Pass
PLCG2 2 ★ ★ ★ ☆ ☆ Pass
IGLL5 2 ★ ★ ★ ★ ☆ Pass
HIST1H3D 2 ★ ★ ★ ☆ ☆ Pass
WNK2 2 ★ ★ ★ ★ ☆ Pass
HIST1H4J 2 ★ ★ ★ ☆ ☆ Pass
IKZF3 2 ★ ★ ★ ☆ ☆ Pass
ZFP36L1 2 ★ ★ ★ ★ ☆ Pass
RNF144B 2 ★ ★ ★ ☆ ☆ Pass
ALPK2 2 ★ ☆ ☆ ☆ ☆ Fail
CD79B 2 ★ ★ ☆ ☆ ☆ Fail
CTCF 2 ★ ☆ ☆ ☆ ☆ Fail
DNMT1 2 ★ ☆ ☆ ☆ ☆ Fail
ETS1 2 ★ ☆ ☆ ☆ ☆ Fail
FZD3 2 ★ ☆ ☆ ☆ ☆ Fail
HIST1H1C 2 ★ ★ ☆ ☆ ☆ Fail
HIST1H2AG 2 ★ ★ ☆ ☆ ☆ Fail
HIST1H2BK 2 ★ ☆ ☆ ☆ ☆ Fail
KCNK10 2 ★ ★ ☆ ☆ ☆ Fail
MME 2 ★ ☆ ☆ ☆ ☆ Fail
MTOR 2 ★ ☆ ☆ ☆ ☆ Fail
PABPC4L 2 ★ ★ ☆ ☆ ☆ Fail
PCDHA11 2 ★ ☆ ☆ ☆ ☆ Fail
PDZRN3 2 ★ ☆ ☆ ☆ ☆ Fail
PIK3R1 2 ★ ☆ ☆ ☆ ☆ Fail
PXDNL 2 ★ ☆ ☆ ☆ ☆ Fail
SNTB2 2 ★ ★ ☆ ☆ ☆ Fail
WDR7 2 ★ ★ ☆ ☆ ☆ Fail
HIST1H3H 2 ☆ ☆ ☆ ☆ ☆ Fail
HIST1H3J 2 ☆ ☆ ☆ ☆ ☆ Fail
HIST1H2AM 2 ☆ ☆ ☆ ☆ ☆ Fail

Details

Panea, R., C. Love, Jennifer R. Shingleton, Anupama Reddy, J. Bailey, A. Moormann, J. Otieno, et al. 2019. “The Whole Genome Landscape of Burkitt Lymphoma Subtypes.” Blood. https://doi.org/10.1182/blood.2019001880.

Disclaimer

The content in these pages has been populated, in part, by an automated process. Although we have scrutinized every page to ensure accuracy, errors will inevitably exist. If you find an error please report it as an issue and we will address it.

In particular, let us know if you feel that an important citation is missing or if a paper has been cited incorrectly.

License

This work is licensed under a Creative Commons Attribution 4.0 International License.

You are free to:

Share — copy and redistribute the material in any medium or format for any purpose, even commercially.

Adapt — remix, transform, and build upon the material for any purpose, even commercially. The licensor cannot revoke these freedoms as long as you follow the license terms.